Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
MannKind Corporation - Common Stock
(NQ:
MNKD
)
3.490
-0.030 (-0.85%)
Streaming Delayed Price
Updated: 12:21 PM EDT, Jun 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
1,067,731
Open
3.530
Bid (Size)
3.480 (10,200)
Ask (Size)
3.490 (3,200)
Prev. Close
3.520
Today's Range
3.420 - 3.530
52wk Range
2.230 - 6.510
Shares Outstanding
264,305,532
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPF
June 03, 2026
From
MannKind
Via
GlobeNewswire
MannKind Wins FDA Approval for Afrezza in Children, Opening Pediatric Diabetes Market
↗
May 30, 2026
MannKind (NASDAQ:MNKD) said the U.S. Food and Drug Administration has approved Afrezza for pediatric patients with diabetes ages 6 and older, expanding the inhaled mealtime insulin’s label into...
Via
MarketBeat
Performance
YTD
-37.7%
-37.7%
1 Month
+22.0%
+22.0%
3 Month
+23.3%
+23.3%
6 Month
-38.9%
-38.9%
1 Year
-19.8%
-19.8%
More News
Read More
MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval
May 29, 2026
From
MannKind
Via
GlobeNewswire
MannKind Announces FDA Approval of Afrezza®, the First and Only Inhaled Mealtime Insulin for Use in Children and Adolescents Aged 6 and Older Living with Diabetes
May 29, 2026
From
MannKind
Via
GlobeNewswire
MannKind Corp (NASDAQ:MNKD) Q1 2026 Revenue Miss and Wider EPS Loss Overshadow Strong Pipeline Progress
↗
May 06, 2026
Via
Chartmill
MannKind Corp (NASDAQ:MNKD) Reports Q4 2025 Revenue Beat and Strategic Outlook for 2026
↗
February 26, 2026
Via
Chartmill
MannKind to Present at Jefferies Global Healthcare Conference
May 27, 2026
From
MannKind
Via
GlobeNewswire
MannKind to Showcase New Data at ADA 2026 Advancing Understanding of Inhaled Insulin (Afrezza®) in Pediatric Care, Pregnancy and Use with Automated Insulin Delivery (AID) Systems
May 27, 2026
From
MannKind
Via
GlobeNewswire
MannKind (MNKD) Q1 2026 Earnings Transcript
↗
May 06, 2026
Via
The Motley Fool
MannKind Reports First Quarter 2026 Financial Results and Provides Business Update
May 06, 2026
From
MannKind
Via
GlobeNewswire
Keep an eye on the top gainers and losers in Wednesday's session.
↗
May 06, 2026
Via
Chartmill
Wednesday's session: gap up and gap down stocks
↗
May 06, 2026
Via
Chartmill
MannKind Announces Ralinepag Dry Powder Inhalation (DPI) Program to be Pursued for Pulmonary Hypertension and Fibrotic Lung Diseases
May 06, 2026
From
MannKind
Via
GlobeNewswire
MannKind to Report First Quarter 2026 Financial Results on May 6, 2026
April 29, 2026
From
MannKind
Via
GlobeNewswire
MannKind to Present New Data From Pediatric and Adult Studies of Afrezza® at ATTD 2026
March 09, 2026
From
MannKind
Via
GlobeNewswire
MannKind Announces Settlement of Convertible Senior Notes
March 05, 2026
From
MannKind
Via
GlobeNewswire
MannKind to Participate in Upcoming Investor Conferences
March 04, 2026
From
MannKind
Via
GlobeNewswire
What's Going On With MannKind Stock Friday?
↗
February 27, 2026
Via
Benzinga
Why MannKind Stock Tumbled on Thursday
↗
February 26, 2026
Via
The Motley Fool
MannKind Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
February 26, 2026
From
MannKind
Via
GlobeNewswire
Let's take a look at the stocks that are in motion in today's session.
↗
February 25, 2026
Via
Chartmill
MannKind Stock Plummets After Partner United Therapeutics Unveils New ‘Category Killer Product’
↗
February 25, 2026
Via
Stocktwits
Here are the top movers in Wednesday's session.
↗
February 25, 2026
Via
Chartmill
The market is filled with gapping stocks in Wednesday's session.
↗
February 25, 2026
Via
Chartmill
MannKind to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
February 19, 2026
From
MannKind
Via
GlobeNewswire
Frequently Asked Questions
Is MannKind Corporation - Common Stock publicly traded?
Yes, MannKind Corporation - Common Stock is publicly traded.
What exchange does MannKind Corporation - Common Stock trade on?
MannKind Corporation - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for MannKind Corporation - Common Stock?
The ticker symbol for MannKind Corporation - Common Stock is MNKD on the Nasdaq Stock Market
What is the current price of MannKind Corporation - Common Stock?
The current price of MannKind Corporation - Common Stock is 3.490
When was MannKind Corporation - Common Stock last traded?
The last trade of MannKind Corporation - Common Stock was at 06/05/26 12:21 PM ET
What is the market capitalization of MannKind Corporation - Common Stock?
The market capitalization of MannKind Corporation - Common Stock is 922.43M
How many shares of MannKind Corporation - Common Stock are outstanding?
MannKind Corporation - Common Stock has 922M shares outstanding.
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
